title: [Clinical guidelines for the use of dimethyl fumarate in relapsing-remitting multiple sclerosis].
abstract: Multiple sclerosis is a chronic demyelinating and neurodegenerative disease of the central nervous system, in which autoimmune inflammation and oxidative stress play essential pathogenetic roles. Activation and infiltration of immune cells in brain tissues, lipid peroxidation products, mitochondrial dysfunction, defective antioxidant protection, and many other pathological factors result in demyelination, axonal injury and death, and apoptosis of oligodendrocytes and neurons, all of which causes constant progression of the disease. The new oral agent for the treatment of relapsing-remitting multiple sclerosis (RRMS), dimethyl fumarate (DMF), helps change the pathogenetic mechanisms of the disease, thus decreasing the rate of exacerbations, slowing down disease progression, and reducing the risk of radiological progression of the disease.
authors.affiliation: Siberian State Medical University, Tomsk, Russia.
authors.forename: V M
authors.initials: VM
authors.lastname: Alifirova
authors.affiliation: Pirogov Russian National Research Medical University, Moscow, Russia.
authors.forename: A N
authors.initials: AN
authors.lastname: Boiko
authors.affiliation: Samara State Medical University, Samara, Russia.
authors.forename: Ya V
authors.initials: YV
authors.lastname: Vlasov
authors.affiliation: Pirogov Russian National Research Medical University, Moscow, Russia.
authors.forename: M V
authors.initials: MV
authors.lastname: Davydovskaya
authors.affiliation: Research Center of Neurology, Moscow, Russia.
authors.forename: M N
authors.initials: MN
authors.lastname: Zakharova
authors.affiliation: Novosibirsk State Medical University, Novosibirsk, Russia.
authors.forename: N A
authors.initials: NA
authors.lastname: Malkova
authors.affiliation: Pirogov Russian National Research Medical University, Moscow, Russia.
authors.forename: E V
authors.initials: EV
authors.lastname: Popova
authors.affiliation: Tyumen Regional Center of Multiple Sclerosis, Tyumen, Russia.
authors.forename: S A
authors.initials: SA
authors.lastname: Sivertseva
authors.affiliation: Yaroslavl State Medical University, Yaroslavl, Russia.
authors.forename: N N
authors.initials: NN
authors.lastname: Spirin
authors.affiliation: Pirogov Russian National Research Medical University, Moscow, Russia.
authors.forename: N V
authors.initials: NV
authors.lastname: Khachanova
authors.affiliation: Sechenov First Moscow State Medical University, Moscow, Russia.
authors.forename: Т Е
authors.initials: ТЕ
authors.lastname: Shmidt
mesh_terms: D000069462:Dimethyl Fumarate / Q000494:pharmacology / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D012426:Russia
chemical_list: D007166:Immunosuppressive Agents; D000069462:Dimethyl Fumarate